Glionova
Stockholm
About Glionova
Glionova AB, a development stage biopharmaceutical company, is engaged in the development of therapies for difficult-to-treat cancers. The company develops GLN-1001, an orally bioavailable small molecule that induces selective cell death in glioblastoma cells without causing harm to normal brain tissue.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $5.7M
- Funding stage: Early Stage Venture
- Last round: Series A (Dec 2014)
- Website: glionova.com
- Phone: +46 70 540 6519
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/glionova-3078109 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.